vs
Side-by-side financial comparison of Inventiva S.A. (IVA) and Moleculin Biotech, Inc. (MBRX). Click either name above to swap in a different company.
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients living with fibrosis, rare diseases, and oncological conditions. It advances a pipeline of targeted product candidates, with key operations across Europe and North America, serving patient populations with high unmet medical needs worldwide.
Moleculin Biotech, Inc. is a clinical-stage biotechnology company focused on developing innovative oncology therapies for difficult-to-treat cancers. Its core pipeline includes candidates targeting brain tumors, pancreatic cancer and other rare malignancies, with primary operations in the United States addressing high unmet patient needs.
IVA vs MBRX — Head-to-Head
Income Statement — Q2 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.1K | $0 |
| Net Profit | $-49.0M | $15.6M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | -961352.9% | — |
| Revenue YoY | — | — |
| Net Profit YoY | — | 336.2% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $0 | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $0 | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | $5.1K | $0 | ||
| Q1 24 | — | $0 |
| Q4 25 | — | $15.6M | ||
| Q3 25 | — | $-25.4M | ||
| Q2 25 | — | $-17.8M | ||
| Q1 25 | — | $-5.9M | ||
| Q4 24 | — | $-6.6M | ||
| Q3 24 | — | $-7.0M | ||
| Q2 24 | $-49.0M | $-6.0M | ||
| Q1 24 | — | $-6.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -961352.9% | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.0M | $8.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-85.4M | $15.0M |
| Total Assets | $42.6M | $22.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.9M | ||
| Q3 25 | — | $6.7M | ||
| Q2 25 | — | $7.6M | ||
| Q1 25 | — | $7.7M | ||
| Q4 24 | — | $4.3M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | $11.0M | $10.8M | ||
| Q1 24 | — | $16.8M |
| Q4 25 | — | $15.0M | ||
| Q3 25 | — | $-26.9M | ||
| Q2 25 | — | $-3.6M | ||
| Q1 25 | — | $13.8M | ||
| Q4 24 | — | $11.2M | ||
| Q3 24 | — | $17.4M | ||
| Q2 24 | $-85.4M | $19.4M | ||
| Q1 24 | — | $25.0M |
| Q4 25 | — | $22.1M | ||
| Q3 25 | — | $20.4M | ||
| Q2 25 | — | $21.6M | ||
| Q1 25 | — | $21.0M | ||
| Q4 24 | — | $16.9M | ||
| Q3 24 | — | $23.4M | ||
| Q2 24 | $42.6M | $25.6M | ||
| Q1 24 | — | $30.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-5.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.35× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-5.4M | ||
| Q3 25 | — | $-7.2M | ||
| Q2 25 | — | $-5.6M | ||
| Q1 25 | — | $-4.6M | ||
| Q4 24 | — | $-5.1M | ||
| Q3 24 | — | $-6.1M | ||
| Q2 24 | — | $-5.9M | ||
| Q1 24 | — | $-6.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-6.0M | ||
| Q1 24 | — | — |
| Q4 25 | — | -0.35× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
